Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.
2.

Weekly versus biweekly bortezomib given in patients with indolent non-Hodgkin lymphoma: A meta-analysis.

Yuan T, Zhang F, Yao QM, Liu YX, Zhu XJ, Wang X.

PLoS One. 2017 May 22;12(5):e0177950. doi: 10.1371/journal.pone.0177950. eCollection 2017.

3.

In Vitro Metabolism of Oprozomib, an Oral Proteasome Inhibitor: Role of Epoxide Hydrolases and Cytochrome P450s.

Wang Z, Fang Y, Teague J, Wong H, Morisseau C, Hammock BD, Rock DA, Wang Z.

Drug Metab Dispos. 2017 Jul;45(7):712-720. doi: 10.1124/dmd.117.075226. Epub 2017 Apr 20.

PMID:
28428366
4.

Targeted Drugs as Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma.

Yan F, Gopal AK, Graf SA.

Pharmaceuticals (Basel). 2017 Mar 10;10(1). pii: E28. doi: 10.3390/ph10010028. Review.

5.

Emerging therapies for the treatment of relapsed or refractory follicular lymphoma.

MacDonald D, Prica A, Assouline S, Christofides A, Lawrence T, Sehn LH.

Curr Oncol. 2016 Dec;23(6):407-417. doi: 10.3747/co.23.3405. Epub 2016 Dec 21. Review.

6.

The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma.

Arkwright R, Pham TM, Zonder JA, Dou QP.

Expert Opin Drug Discov. 2017 Feb;12(2):225-235. doi: 10.1080/17460441.2017.1268596. Epub 2016 Dec 20. Review.

PMID:
27917682
7.

PERK Integrates Oncogenic Signaling and Cell Survival During Cancer Development.

Bu Y, Diehl JA.

J Cell Physiol. 2016 Oct;231(10):2088-96. doi: 10.1002/jcp.25336. Epub 2016 Mar 6. Review.

8.

The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?

Dreyling M, Ferrero S; European Mantle Cell Lymphoma Network.

Haematologica. 2016 Feb;101(2):104-14. doi: 10.3324/haematol.2014.119115. Review.

9.

Targeting mTOR for the treatment of B cell malignancies.

Lee JS, Vo TT, Fruman DA.

Br J Clin Pharmacol. 2016 Nov;82(5):1213-1228. doi: 10.1111/bcp.12888. Epub 2016 Mar 3. Review.

10.

Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes.

Vallumsetla N, Paludo J, Kapoor P.

Ther Clin Risk Manag. 2015 Nov 6;11:1663-74. doi: 10.2147/TCRM.S72943. eCollection 2015. Review.

11.

Preferential PPAR-α activation reduces neuroinflammation, and blocks neurodegeneration in vivo.

Esmaeili MA, Yadav S, Gupta RK, Waggoner GR, Deloach A, Calingasan NY, Beal MF, Kiaei M.

Hum Mol Genet. 2016 Jan 15;25(2):317-27. doi: 10.1093/hmg/ddv477. Epub 2015 Nov 24.

12.

Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.

Shah JJ, Jakubowiak AJ, O'Connor OA, Orlowski RZ, Harvey RD, Smith MR, Lebovic D, Diefenbach C, Kelly K, Hua Z, Berger AJ, Mulligan G, Faessel HM, Tirrell S, Dezube BJ, Lonial S.

Clin Cancer Res. 2016 Jan 1;22(1):34-43. doi: 10.1158/1078-0432.CCR-15-1237. Epub 2015 Nov 11.

13.

Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601.

Till BG, Li H, Bernstein SH, Fisher RI, Burack WR, Rimsza LM, Floyd JD, DaSilva MA, Moore DF Jr, Pozdnyakova O, Smith SM, LeBlanc M, Friedberg JW.

Br J Haematol. 2016 Jan;172(2):208-18. doi: 10.1111/bjh.13818. Epub 2015 Oct 22.

14.

Modulatory effects of bortezomib on host immune cell functions.

Pellom ST Jr, Dudimah DF, Thounaojam MC, Sayers TJ, Shanker A.

Immunotherapy. 2015;7(9):1011-22. doi: 10.2217/imt.15.66. Epub 2015 Sep 1. Review.

15.

Arsenic trioxide rewires mantle cell lymphoma response to bortezomib.

Zhao LL, Liu YF, Peng LJ, Fei AM, Cui W, Miao SC, Hermine O, Gressin R, Khochbin S, Chen SJ, Wang J, Mi JQ.

Cancer Med. 2015 Nov;4(11):1754-66. doi: 10.1002/cam4.511. Epub 2015 Aug 26.

16.

Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and IκBα kinase downregulation.

Cowan AJ, Frayo SL, Press OW, Palanca-Wessels MC, Pagel JM, Green DJ, Gopal AK.

Anticancer Drugs. 2015 Oct;26(9):974-83. doi: 10.1097/CAD.0000000000000274.

17.

Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma.

Amengual JE, Johannet P, Lombardo M, Zullo K, Hoehn D, Bhagat G, Scotto L, Jirau-Serrano X, Radeski D, Heinen J, Jiang H, Cremers S, Zhang Y, Jones S, O'Connor OA.

Clin Cancer Res. 2015 Oct 15;21(20):4663-75. doi: 10.1158/1078-0432.CCR-14-3068. Epub 2015 Jun 26.

18.

Targeting Notch1 and proteasome as an effective strategy to suppress T-cell lymphoproliferative neoplasms.

Yang L, Zhang S, George SK, Teng R, You X, Xu M, Liu H, Sun X, Amin HM, Shi W.

Oncotarget. 2015 Jun 20;6(17):14953-69.

19.

Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma.

Leshchenko VV, Kuo PY, Jiang Z, Weniger MA, Overbey J, Dunleavy K, Wilson WH, Wiestner A, Parekh S.

Oncotarget. 2015 Sep 29;6(29):27332-42. doi: 10.18632/oncotarget.2903.

20.

Mantle cell lymphoma: observation to transplantation.

Rajabi B, Sweetenham JW.

Ther Adv Hematol. 2015 Feb;6(1):37-48. doi: 10.1177/2040620714561579. Review.

Supplemental Content

Support Center